The NASS Podcast

Daniel Resnick, MS, MD (Madison, WI), Eeric Truumees, MD (Austin, TX), Zoher Ghogawala, MD (Boston, MA) and Jeffrey Wang, MD (Los Angeles, CA) discuss the trends in treatment of degenerative spondylolisthesis.

Disclosures:

Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Nonfinancial, Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Nonfinancial, Chair).

Resnick, Daniel K.: Scientific Advisory Board: NIDUS (None).

Truumees, Eeric: Board of Directors: Seton Family of Doctors (No additional pay, part of base compensation); Other Office: AAOS Communications Cabinet (E); Research Support (Staff and/or materials): Dova Pharmaceuticals (A, Paid directly to institution/employer), Medtronic (C, Paid directly to institution/employer), Pfizer (E, Paid directly to institution/employer), Relievant (F, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer), Vertex Pharma (D, Study cancelled, Outside 12-Month Requirement, Paid directly to institution/employer); Trips/Travel: AAOS (Travel Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Chris Steyn, MD (McMaster University) and Christina Goldstein MD, FRCSC (University of Missouri) discuss quality of life for patients with metastatic disease of the spine.

Disclosures:

Steyn, Chris : Nothing to Disclose  

Goldstein, Christina L.: Consulting: SpineSource (B); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (B, Paid directly to institution/employer), DePuy Synthes Spine (A); Other Office: North American Spine Society (Nonfinancial, Coverage Committee, Section on Biologics and Basic Research); Grants: University of Missouri Coulter Translational Partnership (C, Paid directly to institution/employer), Musculoskeletal Transplant Foundation (E).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Sigurd Berven, MD (University of California San Francisco) and Michael Y. Wang, MD, FACS (The University of Miami) review proximal junctional kyphosis.

Disclosures:

Berven, Sigurd H.: Consulting: Innovasis (B), Medicrea (C), Medtronic (C); Fellowship Support: Globus Medical (D); Grants: AO Spine (E, Paid directly to institution/employer), Globus (D, Paid directly to institution/employer); Private Investments: Green Sun Medical (50,000 Shares); Royalties: Stryker (F); Scientific Advisory Board: Globus Medical (Stock options); Speaking and/or Teaching Arrangements: Medtronic (B), Stryker Spine (B); Stock Ownership: Globus Medical (25,000 Shares), Providence Medical (2,500 Shares); Trips/Travel: Scoliosis Research Society (Travel Expense Reimbursement, Paid directly to institution/employer).

Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (less than 1%), Medical Device Partners (<1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Thomas E. Dreisinger, PhD, FACSM, Ezequiel D. Gherscovici, PT and Evan K. Johnson, PT, DPT, OCS discuss physical therapy before and after spine surgery.

Disclosures:

Dreisinger, Ted E.: Nothing to Disclose

Gherscovici, Ezequiel D.: Speaking and/or Teaching Arrangements: The McKenzie institute (Financial, USD $4,000).

Johnson, Evan K.: Nothing to Disclose  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

A. Jay Khanna, MD (Johns Hopkins University) and Charles A. Reitman, MD (The Medical University of South Carolina Charleston) discuss management and complication of spine instrumentations in the treatment of osteoporosis.

Disclosures:

Khanna, A. Jay: Consulting: Orthofix Spine (C); Device or Biologic Distribution Group (Physician-Owned Distributorship): Ortho Development (B), Thieme Medical Publishers (B); Grants: Siemens Healthcare (B, Paid directly to institution/employer); Other Office: Johns Hopkins Center for Bioengineering, Innovation and Design (Advisory Board, Paid directly to institution/employer); Private Investments (including venture capital, start-ups): Avitus Orthopaedics (9%), Cortical Concepts (16%), New Era Orthopaedics (15%); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (A).

Reitman, Charles A.: Board of Directors: NASS (Travel Expense Reimbursement); Other: NASS (Nonfinancial); Scientific Advisory Board: Clinical Orthopaedics And Related Research (B, Paid directly to institution/employer).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Scott L. Blumenthal, MD (Texas Back Institute), Rolando Garcia Jr., MD, MPH (Miami, FL) and Gregory D. Schroeder, MD (The Rothman Institute) answer the question of whether surgery is an option for axial back pain.

Disclosures:

Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (<1%), VertiFlex (<1%), Centinel Spine (less than 1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).

Garcia, Rolando: Consulting: Aesculap Implant Systems (C), Centinel Spine (A); Device or Biologic Distribution Group (Physician-Owned Distributorship): Aesculap (C); Scientific Advisory Board: Aesculap Implant System (B); Speaking and/or Teaching Arrangements: Aesculap Implant Systems (Travel Expense Reimbursement); Trips/Travel: Aesculap Implant Systems (Travel Expense Reimbursement).

Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Saralyn Mark, MD (iGIANT, Yale University, Georgetown University) and Gregory Whitcomb, DC (Medical College of Wisconsin) discuss the impact of gender on new technology in spine care.

Disclosures:

Mark, Saralyn: Nothing to Disclose

Whitcomb, Gregory L.: Nothing to Disclose  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Scott L. Blumenthal, MD, Rolando Garcia Jr., MD, MPH and Gregory D. Schroeder, MD debate anterior versus posterior cervical myelopathy.

Disclosures:

Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (less than 1%), VertiFlex (less than 1%), Centinel Spine (less than 1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).

Garcia, Rolando: Consulting: Aesculap Implant Systems (C),  Centinel Spine (A); Device or Biologic Distribution Group (Physician-Owned Distributorship): Aesculap (C); Scientific Advisory Board: Aesculap Implant System (B); Speaking and/or Teaching Arrangements: Aesculap Implant Systems (Travel Expense Reimbursement); Trips/Travel: Aesculap Implant Systems (Travel Expense Reimbursement).

Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Brandon Lawrence, MD (University of Utah) and Harvey E. Smith, MD (University of Pennsylvania Department of Orthopaedic Surgery) discuss cellular-based allografts.

Disclosures:

Lawrence, Brandon Douglas: Board of Directors: AO Spine North America (Nonfinancial, Paid directly to institution/employer),  Cervical Spine Research Society (Nonfinancial, Paid directly to institution/employer); Fellowship Support: AO Spine North America (E, Paid directly to institution/employer); Trips/Travel: AO Spine North America (B, Paid directly to institution/employer).

Smith, Harvey E.: Stock Ownership: Johnson And Johnson (200 Shares, 100.00%); Trips/Travel: Biedermann Medtech (A), Depuy/Johnson&Johnson (A), Nuvasive (Nonfinancial), Stryker (A).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Matthew Smuck, MD (Stanford University) and Joshua E. Heller, MD (Thomas Jefferson University) discuss patient selection for sacroiliac dysfunction.

Disclosure:

Heller, Joshua E.: Consulting: Nuvasive (D),  Providence Medical Technology (D),  SI Bone (C).

Smuck, Matthew: Board of Directors: Spine Intervention Society (None); Consulting: Consultant & expert witness - State Farm (F), Spine Biopharma (Future Compensation Expected); Grants: Relievant Medsystems (F, Paid directly to institution/employer), ReWalk (E, Paid directly to institution/employer); Private Investments: Vivametrica (15.00%); Scientific Advisory Board: BlueJay Mobile-Health (Stock options), NuSpine (Stock options); Stock Ownership: BlueJay Mobile-Health (less than 1%), NuSpine (less than 1%); Trips/Travel: Spine Intervention Society, Board of Directors (B, Travel Expenses).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+